Skip to content

Doximity DOCS Free cash flow

Free cash flow at other companies

Microsoft logo
MicrosoftMSFT
$15.8B-22.1%
Cardinal Health logo
Cardinal HealthCAH
$1.68B-40.0%
Cencora logo
CencoraCOR
-$2.42B+14.2%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
-$34.92M-507%
Solventum logo
SolventumSOLV
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG

Other financials

Income statement

See full
Revenue$145.4M+5.1%
Gross profit$126.0M+1.7%
Operating income$24.8M-49.0%
Net income$19.1M-69.4%
EPS (diluted)$0.10-67.7%

Balance sheet

See full
Cash & equivalents$219.2M+4.6%
Total debt$10.2M-17.8%
Total equity$950.8M-12.2%
Total assets$1.1B-11.1%

Cash flow

See full
Operating cash flow$109.5M+11.2%
CapEx-

Valuation

See full
Market cap$3.74B-60.5%
Enterprise value$3.53B-61.7%
P/E19.1×-23.3×
P/S5.8×-10.8×

Profitability

See full
Gross margin89.1%-1.1pp
Operating margin33.3%-6.6pp
Net margin30.4%-8.7pp
FCF margin50.6%+2.7pp

Returns & leverage

See full
Return on equity19.3%-3.2pp
Debt / equity0.0×
Current ratio6.1×-0.9×

Where this comes from

Calculated from Doximity’s reported figures.

The official record: Doximity’s 10-K, filed May 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Doximity's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Doximity's free cash flow?
Doximity (DOCS) reported free cash flow of $81.61M in Q1 2026.
How has Doximity's free cash flow changed year-over-year?
Doximity's free cash flow decreased by 17.1% year-over-year, from $98.49M to $81.61M.
What is the long-term trend for Doximity's free cash flow?
Over 4 years (2022 to 2026), Doximity's free cash flow has grown at a 27.2% compound annual growth rate (CAGR), from $124.66M to $326.46M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.